Endocyte Hits New 12-Month Low at $6.01 (ECYT)
Shares of Endocyte (NASDAQ:ECYT) reached a new 52-week low during trading on Monday , StockRatingsNetwork.com reports. The stock traded as low as $6.01 and last traded at $6.12, with a volume of 428,785 shares changing hands. The stock had previously closed at $6.23.
Several analysts have recently commented on the stock. Analysts at Brean Capital initiated coverage on shares of Endocyte in a research note on Tuesday, July 8th. They set a “buy” rating and a $22.00 price target on the stock. Separately, analysts at Zacks upgraded shares of Endocyte from a “neutral” rating to an “outperform” rating in a research note on Monday, July 7th. They now have a $7.90 price target on the stock. Finally, analysts at Chardan Capital cut their price target on shares of Endocyte from $26.00 to $15.00 in a research note on Wednesday, June 18th. They now have a “buy” rating on the stock. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $23.49.
The stock has a 50-day moving average of $6.54 and a 200-day moving average of $12.22. The company’s market cap is $251.1 million.
Endocyte (NASDAQ:ECYT) last released its quarterly earnings data on Friday, May 2nd. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.14) by $0.05. The company had revenue of $17.30 million for the quarter, compared to the consensus estimate of $15.07 million. On average, analysts predict that Endocyte will post $-0.18 earnings per share for the current fiscal year.
Endocyte, Inc (NASDAQ:ECYT) is a biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.